Analysts expect Pelthos Therapeutics Inc. to report revenue of 17.14 M for Q3 26, against a range of 15.52 M to 18.77 M. The most recent reported quarter, Q2 26, came in at 15.60 M, a 2.3% miss against the 15.96 M consensus.
| Metric | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 7.41 M | 9.39 M | 10.91 M | 15.60 M | - | - | - | - |
| High Estimate | 0.00 | 4.53 M | 9.85 M | 11.76 M | 16.45 M | 18.77 M | 19.64 M | 22.88 M | 27.96 M |
| Low Estimate | 0.00 | 3.75 M | 9.11 M | 10.02 M | 15.48 M | 15.52 M | 17.68 M | 19.61 M | 24.37 M |
| Consensus Estimate | 0.00 | 4.14 M | 9.48 M | 10.89 M | 15.96 M | 17.14 M | 18.66 M | 21.25 M | 26.17 M |
Analysts expect Pelthos Therapeutics Inc. to report earnings per share of -3.23 for Q2 24, against a range of -3.48 to -2.98. The most recent reported quarter, Q2 26, came in at -6.62, a 148.9% miss against the -2.66 consensus.
| Metric | Q2 24 | Q3 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | - | -3.21 | -5.38 | -5.30 | -6.87 | -3.09 | -6.62 | - | - | - | - |
| High Estimate | -2.98 | -2.06 | -2.63 | -5.00 | -0.57 | -3.14 | -3.32 | -2.58 | -2.99 | -2.47 | -1.08 | -0.50 |
| Low Estimate | -3.48 | -2.26 | -2.91 | -5.90 | -0.63 | -3.84 | -3.90 | -2.74 | -3.21 | -2.79 | -1.26 | -0.60 |
| Consensus Estimate | -3.23 | -2.16 | -2.77 | -5.45 | -0.60 | -3.49 | -3.61 | -2.66 | -3.10 | -2.63 | -1.17 | -0.55 |